Novo Nordisk A/S

NVO

55.230USD

-0.910-1.62%

Close 09/05, 16:00（ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

97 / 686

Overall Ranking

205 / 4732

Industry

Pharmaceuticals & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 11 analysts

Hold

Current Rating

67.139

Target Price

+18.33%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Novo Nordisk A/S is a Danish multinational pharmaceutical firm headquartered in Bagsværd, with manufacturing facilities across nine countries and affiliates or offices in five others. The company is predominantly controlled by its majority shareholder, Novo Holdings A/S, which owns approximately 28.1% of its shares and a majority of its voting rights.

Novo Nordisk specializes in the production and marketing of pharmaceutical products and services, focusing primarily on diabetes care medications and devices. Among its key products is semaglutide, utilized for diabetes treatment under the brand names Ozempic and Rybelsus, as well as for obesity treatment under the brand name Wegovy. The company also engages in hemostasis management, growth hormone therapy, and hormone replacement therapy, producing numerous drugs under various brand names such as Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.

Employing over 48,000 individuals worldwide, Novo Nordisk distributes its products in 168 countries. The corporation was formed in 1989 from a merger of two Danish companies with origins tracing back to the 1920s. The Novo Nordisk logo features the Apis bull, a sacred animal from ancient Egypt, represented by the hieroglyph 𓃒. Novo Nordisk is also a full member of the European Federation of Pharmaceutical Industries and Associations.

Recognized for its workplace culture, the company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, later ranking 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was acclaimed as the most sustainable company globally by Corporate Knights, while its spin-off, Novozymes, secured the fourth position. The company is a leader in the FTSE4Good Index and stands as the only European firm in the top ten list. As the largest pharmaceutical company in Denmark, Novo Nordisk's market capitalization surpassed the GDP of Denmark's domestic economy in 2023, making it the highest valued company in Europe, with net sales reaching US$42.121 billion in 2024.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 68.35% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 86.57.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 50.19%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 50.19%.

Undervalued

The company’s latest PE is 15.43, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 330.35M shares, decreasing 8.63% quarter-over-quarter.

Held by Ken Fisher

Star Investor Ken Fisher holds 11.00M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.63.

The company's current financial score is 7.31, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.80. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 11.01B, representing a year-over-year increase of 15.63%, while its net profit experienced a year-over-year increase of 10.58%.

Score

Industry at a Glance

Previous score

7.31

Change

0



Financials

7.85

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.11

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.53

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.84

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.23

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 4.80, which is higher than the Pharmaceuticals & Medical Research industry's average of 1.64. Its current P/E ratio is 15.52, which is 177.81% below the recent high of 43.10 and -120.94% above the recent low of 34.28.

Score

Industry at a Glance

Previous score

4.80

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 97/686

No Data

The company’s current earnings forecast score is 6.75, which is lower than the Pharmaceuticals & Medical Research industry's average of 7.96. The average price target for Novo Nordisk A/S is 61.00, with a high of 100.00 and a low of 50.00.

Score

Industry at a Glance

Previous score

6.18

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 9.54, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 61.50 and the support level at 48.21, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.42

Change

-0.23

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-09-04

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals & Medical Research industry's average of 6.02. The latest institutional shareholding proportion is 9.82%, representing a quarter-over-quarter decrease of 1.70%. The largest institutional shareholder is Ken Fisher, holding a total of 11.00M shares, representing 0.33% of shares outstanding, with 12.92% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Jennison Associates LLC

18.82M

-5.63%

Fidelity Management & Research Company LLC

8.98M

-9.18%

Loomis, Sayles & Company, L.P.

12.39M

+7.06%

Capital International Investors

9.51M

+40.82%

Fisher Investments

Star Investors

11.87M

-6.09%

Fayez Sarofim & Co.

11.21M

-1.51%

Folketrygdfondet

9.52M

+6.94%

Managed Account Advisors LLC

8.61M

-8.25%

ClearBridge Investments, LLC

6.63M

+54.88%

Everett Harris & Co.

6.41M

-0.70%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 3.11, which is lower than the Pharmaceuticals & Medical Research industry's average of 3.51. The company's beta value is 0.65. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Novo Nordisk A/S

NVO

6.23 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

7.61 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

7.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Stoke Therapeutics Inc

STOK

7.49 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

7.40 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Innoviva Inc

INVA

7.39 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.